Opus Genetics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$50M
↑+36.3% +$13Mvs FY2024
Total Liabilities
$35M
↑+208.9% +$24Mvs FY2024
Equity
$15M
↑+128.3% +$9Mvs FY2024
Cash
$45M
↑+48.7% +$15Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $50M | $37M |
| Current Assets | $50M | $37M |
| Cash | $45M | $30M |
| ST Investments | $0 | $2K |
| Receivables | $2M | $4M |
| Inventory | $0 | $0 |
| Other Current | $3M | $3M |
| Non-Current Assets | $199K | $252K |
| PPE | $199K | $252K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $0 | $0 |
| Total Liab+Eq | $50M | $18M |
| Current Liab. | $8M | $11M |
| Accounts Payable | $3M | $3M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $4M | $8M |
| Non-Current Liab. | $27M | $0 |
| Long-Term Debt | $1M | $0 |
| Other LT Liab. | $26M | $0 |
| Equity | $15M | $7M |
| Retained Earnings | $189M | $139M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · IRD · Comparing FY2025 vs FY2024